FDA 022
Alternative Names: FDA-022; FDA-022 ADC; FDA-022 antibody drug conjugate; FDA022-BB05Latest Information Update: 20 May 2024
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 May 2024 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans a phase II trial for Solid tumor (Late-stage disease, Inoperable/unresctable, Metastatic diseases, Second-line therapy or greater) in China (IV) in May 2024 (NCT06413615)
- 16 Jan 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) (NCT05564858)
- 10 Oct 2022 Preclinical trials in Solid tumours in China (IV)